Immuneering Corporation IMRX
3.68 USD +0.19 (+5.44%)
At closeNov 3, 2026, 4:01 PM EST
3.68 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
3.52 Day range 3.76
3.38 52-week range 8.48
- YTD
- -44.07%
- 1 year
- -43.90%
Analyst view
Consensus: buy
Buy
Price target (mean) 12.42 +237.4% upside
Now 3.68
- Target (low)
- 1.50
- Target (mean)
- 12.42
- Target (high)
- 25.00
Ratings (0m) 7 5 buy · 1 hold · 1 sell
- Strong buy2
- Buy3
- Hold1
- Sell1
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.39167 | -0.59 – -0.23 | -0.52 | +24.7% | 0 | 0.0% | 6 |
| Next quarter | -0.41 | -0.41 – -0.41 | -0.49 | +16.3% | 0 | 0.0% | 1 |
| Current year | -1.79 | -2.05 – -1.47 | -1.88 | +4.6% | 0 | 0.0% | 6 |
| Next year | -1.63 | -2.36 – -0.92 | -1.79 | +9.2% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 14, 2024 | Needham | Reiterated | Buy | Buy |
| Sep 13, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 7, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 7, 2024 | Needham | Reiterated | Buy | Buy |
| May 8, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 12, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 2, 2024 | Mizuho | Maintained | Buy | Buy |
| Mar 15, 2024 | Jefferies | Downgrade | Buy | Hold |
| Mar 15, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Mar 15, 2024 | Needham | Maintained | Buy | Buy |
| Mar 15, 2024 | TD Cowen | Downgrade | Outperform | Market Perform |
| Mar 14, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Mar 11, 2024 | Needham | Reiterated | Buy | Buy |
| Mar 5, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 4, 2024 | Needham | Reiterated | Buy | Buy |
| Feb 1, 2024 | Needham | Reiterated | Buy | Buy |
| Dec 1, 2023 | Needham | Initiated | — | Buy |
| Aug 8, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 7, 2023 | Chardan Capital | Reiterated | Buy | Buy |
| Aug 4, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Apr 19, 2023 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| Apr 19, 2023 | Mizuho | Upgrade | Neutral | Buy |
| Apr 19, 2023 | Chardan Capital | Maintained | — | Buy |
| Apr 18, 2023 | Chardan Capital | Maintained | — | Buy |
| Mar 30, 2023 | Mizuho | Initiated | — | Neutral |
| Mar 7, 2023 | Chardan Capital | Reiterated | — | Buy |
| Feb 3, 2023 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Jul 15, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jul 8, 2022 | Chardan Capital | Initiated | — | Buy |